2 Apr 2015 14:00
Venn Life Sciences Holdings Plc
("Venn" or the "Company" or the "Group")
Investor teach-in
Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, will be hosting a teach-in where Tony Richardson, CEO will provide an overview and strategy of the Company on Tuesday 21 April 2015. No new material trading or financial information will be disclosed.
The event is open to all investors and analysts and will be held from 16:30 until 19:30 in the Black Bar at Rocket Bar, 6 Adams Court, Old Broad Street, London, EC2N 1DX and will be followed by drinks and canapés.
To register for the event, please email venn@walbrookpr.com or call the Walbrook PR team below.
Enquiries:
Venn Life Sciences Holdings Plc | www.vennlifesciences.com |
Tony Richardson, Chief Executive Officer | Tel: +353 154 99 341 |
Orla Mc Guinness, Marketing Manager
| Tel: +33 676 93 11 78 |
Zeus Capital (Nominated Adviser and Broker) |
|
Ross Andrews/Andrew Jones | Tel: 0161 831 1512 |
Alex Davies | Tel: 020 7533 7727 |
|
|
Walbrook PR Ltd | Tel: +44 (0)20 7933 8780 or venn@walbrookpr.com |
Paul McManus | Mob: +44 (0)7980 541 893 |
Lianne Cawthorne | Mob: +44 (0)7584 391 303 |
About Venn Life Sciences Limited:
Venn Life Sciences is a Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn recently established an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.